2-氟-4-甲氧基吡啶 | 175965-83-0

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-氟-4-甲氧基吡啶
• 英文名称: 2-fluoro-4-methoxypyridine
• CAS: 175965-83-0
• 化学式: C₆H₆FNO
• 分子量: 127.118
• InChiKey: ILAHVONGWYINEB-UHFFFAOYSA-N

物化性质

• 沸点：
  166.6±20.0 °C(Predicted)
• 密度：
  1.146

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H227,H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Fluoro-4-methoxypyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Fluoro-4-methoxypyridine
CAS number: 175965-83-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H6FNO
Molecular weight: 127.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氟-4-甲氧基吡啶 在 potassium tert-butylate 、 potassium carbonate 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 90.33h， 生成 {1-[({7-[(2,6-difluorobenzyl)oxy]-5-methoxy-2-methylpyrazolo[1,5-a]pyridin-3-yl}carbonyl)-amino]-2-methylpentan-2-yl}-carbamic acid tert-butyl ester
  参考文献：
  名称：

  TW2016/5850

  摘要：

  公开号：
• 作为产物：
  描述：

  4-甲氧基吡啶 在 silver(II) fluoride 作用下， 以 乙腈 为溶剂， 反应 1.0h， 以75%的产率得到2-氟-4-甲氧基吡啶
  参考文献：
  名称：

  受经典胺化反应启发的吡啶和二嗪的选择性 CH 氟化

  摘要：

  氟化吡啶 将氟取代基附加到碳中心通常用于调节药物和农业化学研究中的小分子特性。然而，氟化通常需要使用腐蚀性、危险的试剂。Fier 和 Hartwig (p. 956) 提出了一种异常温和且方便的方案，用于氟化吡啶和相关含氮芳烃中与氮相邻的碳位点。该反应需要用二氟化银处理并在室温下快速进行。温和的氟化方法可以帮助生产医学研究中感兴趣的化合物。氟化杂环广泛存在于药物、农用化学品和材料中。然而，将氟结合到杂芳烃中的反应范围有限并且可能是危险的。我们提出了一种广泛适用且安全的方法，用于使用市售的氟化银 (II) 对吡啶和二嗪中的单个碳氢键进行位点选择性氟化。反应在环境温度下在 1 小时内发生，并且对氮附近的氟化具有唯一的选择性。温和的条件允许获得具有重要医学意义的化合物的氟化衍生物，以及通过随后的氟化物亲核置换制备的一系列 2-取代吡啶。机理研究表明，经典的吡啶胺化途径可适用于广泛范围的氮杂环的选择性氟化。反应在环境温度下在

  DOI：

  10.1126/science.1243759

文献信息

• [EN] PYRROLIDINE OREXIN RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS PYRROLIDINE EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE L'HYPOCRÉTINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2016095204A1

  公开（公告）日：2016-06-23

  The present invention is directed to pyrrolidine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及对促进素受体的拮抗剂吡咯烷化合物。本发明还涉及所述化合物在潜在的治疗或预防涉及促进素受体的神经和精神疾病和疾病中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在的预防或治疗涉及促进素受体的疾病中的用途。
• [EN] 2-PYRIDYLOXY-4-ETHER OREXIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES 2-PYRIDYLOXY-4-ÉTHER DES RÉCEPTEURS DE L'OREXINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2014137883A1

  公开（公告）日：2014-09-12

  The present invention is directed to 2-pyridyloxy-4-ether compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-4-ether compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved..

  本发明涉及2-吡啶氧基-4-醚化合物，这些化合物是促进睡眠的受体拮抗剂。本发明还涉及在潜在治疗或预防神经系统和精神疾病中使用本文所述的2-吡啶氧基-4-醚化合物。本发明还涉及包括这些化合物的药物组合物。本发明还涉及在预防或治疗涉及促进睡眠的受体的这些疾病中使用这些药物组合物。
• [EN] C5-C6-OXACYCLIC FUSED IMINOPYRIMIDINONE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE<br/>[FR] COMPOSÉS IMINOPYRIMIDINONES CONDENSÉS OXACYCLIQUES EN C5-C6 UTILISÉS COMME INHIBITEURS DE BACE, COMPOSITIONS ET UTILISATION ASSOCIÉES
  申请人：MERCK SHARP & DOHME

  公开号：WO2016085780A1

  公开（公告）日：2016-06-02

  In its many embodiments, the present invention provides certain C5-C6-oxacyclic fused iminopyrimidinone compounds, including compounds Formula (I): or a tautomer thereof, and pharmaceutically acceptable salts of said compounds and said tautomers, wherein RN, R1, RA, ring A, m, n, -L1-, ring B, RB, and p are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.

  在其多种实施方式中，本发明提供了某些C5-C6-氧杂环融合咪唑嘧啶酮化合物，包括化合物式（I）所示的化合物或其互变异构体，以及该化合物和该互变异构体的药学上可接受的盐，其中RN、R1、RA、环A、m、n、-L1-、环B、RB和p如本文所定义。本发明的新化合物可用作BACE抑制剂和/或用于治疗和预防与之相关的各种病理。还披露了包括一种或多种此类化合物（单独使用和与一种或多种其他活性剂组合使用）的药物组合物，以及其制备和使用方法，包括可能用于治疗阿尔茨海默病的方法。
• SUBSTITUTED PYRAZOLO[1,5-A]-PYRIDINE-3-CARBOXAMIDES AND USE THEREOF
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20160185775A1

  公开（公告）日：2016-06-30

  The present application relates to novel pyrazolo[1,5-a]pyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.

  本申请涉及新型吡唑并[1,5-a]吡啶-3-羧酰胺、其制备方法、其单独或与其他药物联合治疗和/或预防疾病的用途，以及其用于制备治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病。
• 2-PYRIDYLOXY-4-ETHER OREXIN RECEPTOR ANTAGONISTS
  申请人：KUDUK Scott D.

  公开号：US20160016935A1

  公开（公告）日：2016-01-21

  The present invention is directed to 2-pyridyloxy-4-ether compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-4-ether compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及2-吡啶氧基-4-醚类化合物，其为促进睡眠荷尔蒙受体的拮抗剂。本发明还涉及使用此处所述的2-吡啶氧基-4-醚类化合物在潜在的神经和精神障碍和疾病的治疗或预防中，其中促进睡眠荷尔蒙受体发挥作用。本发明还涉及包含这些化合物的药物组合物。本发明还涉及使用这些药物组合物在预防或治疗促进睡眠荷尔蒙受体发挥作用的疾病中。